Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system

Advanced prostate cancer is treated by androgen ablation and/or androgen receptor (AR) antagonists. In order to investigate the mechanisms relevant to the development of therapy-resistant tumours, we established a new tumour model which closely resembles the situation in patients who receive androge...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Culig, Z, Hoffmann, J, Erdel, M, Eder, I E, Hobisch, A, Hittmair, A, Bartsch, G, Utermann, G, Schneider, M R, Parczyk, K, Klocker, H
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 1999
Assuntos:
Regular Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2362859/
https://ncbi.nlm.nih.gov/pubmed/10496349
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6690684
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados